RYZODEG 70/30
PeakBLASUBCUTANEOUSSOLUTION
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYZODEG 70/30 is a fixed-ratio insulin combination (70% insulin degludec + 30% insulin aspart) administered as a subcutaneous injection. It is indicated for type 1 and type 2 diabetes mellitus requiring insulin therapy. The dual-component formulation provides basal coverage via long-acting degludec and mealtime control via rapid-acting aspart.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30), suggesting stable but competitive commercial environment and likely established cross-functional team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RYZODEG is a mature insulin franchise product with established commercial infrastructure but limited growth pipeline activity. Roles are primarily commercial and sales-oriented, focused on market maintenance and competitive differentiation in a crowded insulin landscape.
Brand ManagerField Sales Representative
Worked on RYZODEG 70/30 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.